{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:15:51Z","timestamp":1791954951769,"version":"4.3.4"},"reference-count":221,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The most prevalent chronic neurodegenerative illness in the world is Alzheimer\u2019s disease (AD). It results in mental symptoms including behavioral abnormalities and cognitive impairment, which have a substantial financial and psychological impact on the relatives of the patients. The review discusses various pathophysiological mechanisms contributing to AD, including amyloid beta, tau protein, inflammation, and other factors, while emphasizing the need for effective disease-modifying therapeutics that alter disease progression rather than merely alleviating symptoms. This review mainly covers medications that are now being studied in clinical trials or recently approved by the FDA that fall under the disease-modifying treatment (DMT) category, which alters the progression of the disease by targeting underlying biological mechanisms rather than merely alleviating symptoms. DMTs focus on improving patient outcomes by slowing cognitive decline, enhancing neuroprotection, and supporting neurogenesis. Additionally, the review covers amyloid-targeting therapies, tau-targeting therapies, neuroprotective therapies, and others. This evaluation specifically looked at studies on FDA-approved novel DMTs in Phase II or III development that were carried out between 2021 and 2024. A thorough review of the US government database identified clinical trials of biologics and small molecule drugs for 14 agents in Phase I, 34 in Phase II, and 11 in Phase III that might be completed by 2028.<\/jats:p>","DOI":"10.3390\/molecules29215131","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T09:57:36Z","timestamp":1730368656000},"page":"5131","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Recent Advances in Therapeutics for the Treatment of Alzheimer\u2019s Disease"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0672-9439","authenticated-orcid":false,"given":"Amin Mahmood","family":"Thawabteh","sequence":"first","affiliation":[{"name":"Department of Chemistry, Birzeit University, Birzeit P.O. Box 14, West Bank, Palestine"},{"name":"Faculty of Pharmacy, Nursing and Health Professions, Birzeit University, Birzeit P.O. Box 14, West Bank, Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8634-207X","authenticated-orcid":false,"given":"Aseel Wasel","family":"Ghanem","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Nursing and Health Professions, Birzeit University, Birzeit P.O. Box 14, West Bank, Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1274-402X","authenticated-orcid":false,"given":"Sara","family":"AbuMadi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Nursing and Health Professions, Birzeit University, Birzeit P.O. Box 14, West Bank, Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Thaher","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Nursing and Health Professions, Birzeit University, Birzeit P.O. Box 14, West Bank, Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7852-1621","authenticated-orcid":false,"given":"Weam","family":"Jaghama","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Nursing and Health Professions, Birzeit University, Birzeit P.O. Box 14, West Bank, Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donia","family":"Karaman","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem 20002, Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-4490","authenticated-orcid":false,"given":"Rafik","family":"Karaman","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem 20002, Palestine"},{"name":"Department of Sciences, University of Basilicata, Via dell\u2019Ateneo Lucano 10, 85100 Potenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1038\/s41467-022-31037-5","article-title":"Multimodal Deep Learning for Alzheimer\u2019s Disease Dementia Assessment","volume":"13","author":"Qiu","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hassan, N.A., Alshamari, A.K., Hassan, A.A., Elharrif, M.G., Alhajri, A.M., Sattam, M., and Khattab, R.R. (2022). Advances on Therapeutic Strategies for Alzheimer\u2019s Disease: From Medicinal Plant to Nanotechnology. Molecules, 27.","DOI":"10.3390\/molecules27154839"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ekundayo, T.C., Olasehinde, T.A., Okaiyeto, K., and Okoh, A.I. (2021). Microbial Pathogenesis and Pathophysiology of Alzheimer\u2019s Disease: A Systematic Assessment of Microorganisms\u2019 Implications in the Neurodegenerative Disease. Front. Neurosci., 15.","DOI":"10.3389\/fnins.2021.648484"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Toader, C., Dobrin, N., Brehar, F.-M., Popa, C., Covache-Busuioc, R.-A., Glavan, L.A., Costin, H.P., Bratu, B.-G., Corlatescu, A.D., and Popa, A.A. (2023). From Recognition to Remedy: The Significance of Biomarkers in Neurodegenerative Disease Pathology. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216119"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.31662\/jmaj.2022-0079","article-title":"Molecular Pathogenesis and Disease-modifying Therapies of Alzheimer\u2019 s Disease and Related Disorders","volume":"5","author":"Iwatsubo","year":"2022","journal-title":"JMA J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13195-022-00984-y","article-title":"Meaningful benefits: A framework to assess disease-modifying therapies in preclinical and early Alzheimer\u2019s disease","volume":"14","author":"Sperling","year":"2022","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Chen, Z.-R., Huang, J.-B., Yang, S.-L., and Hong, F.-F. (2022). Role of Cholinergic Signaling in Alzheimer\u2019s Disease. Molecules, 27.","DOI":"10.3390\/molecules27061816"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: Mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1093\/brain\/awac096","article-title":"Reimagining cholinergic therapy for Alzheimer\u2019s disease","volume":"145","author":"Giacobini","year":"2022","journal-title":"Brain"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10522-020-09860-4","article-title":"Alzheimer\u2019s disease: Targeting the glutamatergic system","volume":"21","author":"Conway","year":"2020","journal-title":"Biogerontology"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ma, C., Hong, F., and Yang, S. (2022). Amyloidosis in Alzheimer\u2019s Disease: Pathogeny, Etiology, and Related Therapeutic Directions. Molecules, 27.","DOI":"10.3390\/molecules27041210"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The Amyloid-\u03b2 Pathway in Alzheimer\u2019s Disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.ijbiomac.2020.07.327","article-title":"Role of tau protein in Alzheimer\u2019s disease: The prime pathological player","volume":"163","author":"Muralidar","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/alz.12192","article-title":"Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer\u2019s disease","volume":"17","author":"Arnsten","year":"2020","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3233\/ADR-200171","article-title":"Alzheimer\u2019s Disease, Inflammation, and the Role of Antioxidants","volume":"4","author":"Sinyor","year":"2020","journal-title":"J. Alzheimer\u2019s Dis. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101317","DOI":"10.1016\/j.arr.2021.101317","article-title":"Inflammatory pathways in Alzheimer\u2019s disease mediated by gut microbiota","volume":"68","author":"Qian","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wiatrak, B., Balon, K., Jawie\u0144, P., Bednarz, D., J\u0119\u015bkowiak, I., and Szel\u0105g, A. (2022). The Role of the Microbiota-Gut-Brain Axis in the Development of Alzheimer\u2019s Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094862"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"105314","DOI":"10.1016\/j.phrs.2020.105314","article-title":"The impact of the microbiota-gut-brain axis on Alzheimer\u2019s disease pathophysiology","volume":"164","author":"Doifode","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_19","first-page":"94","article-title":"Oxidative Stress in the Pathogenesis of Alzheimer\u2019s Disease and Cerebrovascular Disease with Therapeutic Implications","volume":"19","author":"Jurcau","year":"2020","journal-title":"CNS Neurol. Disord.\u2014Drug Targets"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101619","DOI":"10.1016\/j.arr.2022.101619","article-title":"Oxidative stress: The core pathogenesis and mechanism of Alzheimer\u2019s disease","volume":"77","author":"Bai","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chen, L.-L., Fan, Y.-G., Zhao, L.-X., Zhang, Q., and Wang, Z.-Y. (2022). The metal ion hypothesis of Alzheimer\u2019s disease and the anti-neuroinflammatory effect of metal chelators. Bioorganic Chem., 131.","DOI":"10.1016\/j.bioorg.2022.106301"},{"key":"ref_22","first-page":"797","article-title":"Autophagy Dysfunction in Alzheimer\u2019s Disease: Mechanistic Insights and New Therapeutic Opportunities","volume":"87","author":"Curtis","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2174\/1567205015666181004143432","article-title":"The Implications of Autophagy in Alzheimer\u2019s Disease","volume":"15","author":"Hamano","year":"2018","journal-title":"Curr. Alzheimer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/ageing\/afab044","article-title":"Neuropsychiatric symptoms in early stage of Alzheimer\u2019s and non-Alzheimer\u2019s dementia, and the risk of progression to severe dementia","volume":"50","author":"Liew","year":"2021","journal-title":"Age Ageing"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jagp.2020.07.011","article-title":"The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases","volume":"29","author":"Cummings","year":"2021","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wiels, W.A., Wittens, M.M.J., Zeeuws, D., Baeken, C., and Engelborghs, S. (2021). Neuropsychiatric Symptoms in Mild Cognitive Impairment and Dementia Due to AD: Relation with Disease Stage and Cognitive Deficits. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.707580"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamapsychiatry.2021.4363","article-title":"Associations Between Neuropsychiatric Symptoms and Neuropathological Diagnoses of Alzheimer Disease and Related Dementias","volume":"79","author":"Devanand","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/23279095.2019.1630626","article-title":"Signs and symptoms method in neuropsychology: A preliminary investigation of a standardized clinical interview for assessment of cognitive decline in dementia","volume":"28","author":"Abbate","year":"2019","journal-title":"Appl. Neuropsychol. Adult"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40120-022-00338-8","article-title":"Alzheimer\u2019s Disease: Epidemiology and Clinical Progression","volume":"11","author":"Monfared","year":"2022","journal-title":"Neurol. Ther."},{"key":"ref_31","first-page":"2201","article-title":"Detecting the Stages of Alzheimer\u2019s Disease with Pre-trained Deep Learning Architectures","volume":"47","year":"2021","journal-title":"Arab. J. Sci. Eng."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s43587-023-00410-4","article-title":"Detection and treatment of Alzheimer\u2019s disease in its preclinical stage","volume":"3","author":"Rafii","year":"2023","journal-title":"Nat. Aging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.molmed.2022.05.008","article-title":"Staging of Alzheimer\u2019s disease: Past, present, and future perspectives","volume":"28","author":"Therriault","year":"2022","journal-title":"Trends Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Recommendations of the International Working Group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"37454","DOI":"10.52965\/001c.37454","article-title":"Impact of Alzheimer\u2019s Disease on Caregivers in the United States","volume":"10","author":"Vu","year":"2022","journal-title":"Health Psychol. Res."},{"key":"ref_36","first-page":"12334","article-title":"Alzheimer\u2019s disease diagnosis and management: Perspectives from around the world","volume":"14","author":"Kerwin","year":"2022","journal-title":"Alzheimer\u2019s Dement. Diagn. Assess. Dis. Monit."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Breijyeh, Z., and Karaman, R. (2020). Comprehensive Review on Alzheimer\u2019s Disease: Causes and Treatment. Molecules, 25.","DOI":"10.3390\/molecules25245789"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Prajapati, V., Shinde, S., Shrivastav, P., and Prajapati, B.G. (2024). New biologicals and biomaterials in the therapy of Alzheimer\u2019s disease. Alzheimer\u2019s Disease and Advanced Drug Delivery Strategies, Academic Press.","DOI":"10.1016\/B978-0-443-13205-6.00016-9"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.conb.2019.11.024","article-title":"Genetics of Alzheimer\u2019s disease: Where we are, and where we are going","volume":"61","author":"Bellenguez","year":"2020","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Neuner, S.M., Tcw, J., and Goate, A.M. (2020). Genetic architecture of Alzheimer\u2019s disease. Neurobiol. Dis., 143.","DOI":"10.1016\/j.nbd.2020.104976"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s10038-022-01050-z","article-title":"Genetics of Alzheimer\u2019s disease: An East Asian perspective","volume":"68","author":"Miyashita","year":"2022","journal-title":"J. Hum. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"108224","DOI":"10.1016\/j.celrep.2020.108224","article-title":"PICALM Rescues Endocytic Defects Caused by the Alzheimer\u2019s Disease Risk Factor APOE4","volume":"33","author":"Narayan","year":"2020","journal-title":"Cell Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcdb.2022.07.011","article-title":"The role of genetic risk factors of Alzheimer\u2019s disease in synaptic dysfunction","volume":"139","author":"Fu","year":"2023","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Flores-Cordero, J.A., P\u00e9rez-P\u00e9rez, A., Jim\u00e9nez-Cortegana, C., Alba, G., Flores-Barrag\u00e1n, A., and S\u00e1nchez-Margalet, V. (2022). Obesity as a Risk Factor for Dementia and Alzheimer\u2019s Disease: The Role of Leptin. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23095202"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5455\/msm.2020.32.299-306","article-title":"Toxic Environmental Factors and their Association with the Development of Dementia: A Mini Review on Heavy Metals and Ambient Particulate Matter","volume":"32","author":"Antoniadou","year":"2020","journal-title":"Mater. Socio Medica"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"184","DOI":"10.18433\/J3VS8P","article-title":"Alzheimer\u2019s Disease: Dawn of a New Era?","volume":"20","author":"Amirrad","year":"2017","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Islam, F., Shohag, S., Akhter, S., Islam, M.R., Sultana, S., Mitra, S., Chandran, D., Khandaker, M.U., Ashraf, G.M., and Idris, A.M. (2022). Exposure of metal toxicity in Alzheimer\u2019s disease: An extensive review. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.903099"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Rehman, Q., Rehman, K., and Akash, M.S.H. (2021). Heavy Metals and Neurological Disorders: From Exposure to Preventive Interventions. Emerging Contaminants and Associated Treatment Technologies, Springer International Publishing.","DOI":"10.1007\/978-3-030-66376-6_4"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3233\/JAD-200289","article-title":"Air Pollution as Risk Factor for Mental Disorders: In Search for a Possible Link with Alzheimer\u2019s Disease and Schizophrenia","volume":"76","author":"Attademo","year":"2020","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"112318","DOI":"10.1016\/j.envres.2021.112318","article-title":"Impact of air pollution exposure on the risk of Alzheimer\u2019s disease in China: A community-based cohort study","volume":"205","author":"He","year":"2022","journal-title":"Environ. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e944","DOI":"10.1212\/WNL.0000000000200774","article-title":"Association of Healthy Lifestyles with Risk of Alzheimer Disease and Related Dementias in Low-Income Black and White Americans","volume":"99","author":"Yang","year":"2022","journal-title":"Neurology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3233\/JAD-220267","article-title":"Modifiable Lifestyle Activities Affect Cognition in Cognitively Healthy Middle-Aged Individuals at Risk for Late-Life Alzheimer\u2019s Disease","volume":"91","author":"Heneghan","year":"2023","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Shafighi, K., Villeneuve, S., Neto, P.R., Badhwar, A., Poirier, J., Sharma, V., Medina, Y.I., Silveira, P.P., Dube, L., and Glahn, D. (2023). Social isolation is linked to classical risk factors of Alzheimer\u2019s disease-related dementias. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0280471"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/alz.12114","article-title":"Refined carbohydrate-rich diet is associated with long-term risk of dementia and Alzheimer\u2019s disease in apolipoprotein E \u03b54 allele carriers","volume":"16","author":"Gentreau","year":"2020","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Frausto, D.M., Forsyth, C.B., Keshavarzian, A., and Voigt, R.M. (2021). Dietary Regulation of Gut-Brain Axis in Alzheimer\u2019s Disease: Importance of Microbiota Metabolites. Front. Neurosci., 15.","DOI":"10.3389\/fnins.2021.736814"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Ellouze, I., Sheffler, J., Nagpal, R., and Arjmandi, B. (2023). Dietary Patterns and Alzheimer\u2019s Disease: An Updated Review Linking Nutrition to Neuroscience. Nutrients, 15.","DOI":"10.3390\/nu15143204"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"102091","DOI":"10.1016\/j.arr.2023.102091","article-title":"Role of diet and exercise in aging, Alzheimer\u2019s disease, and other chronic diseases","volume":"91","author":"Khemka","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"111355","DOI":"10.1016\/j.nut.2021.111355","article-title":"Dietary fatty acids and risk for Alzheimer\u2019s disease, dementia, and mild cognitive impairment: A prospective cohort meta-analysis","volume":"90","author":"Zhu","year":"2021","journal-title":"Nutrition"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1001\/jamapsychiatry.2019.2332","article-title":"Setbacks and Opportunities in Disease-Modifying Therapies in Alzheimer Disease","volume":"77","author":"Forester","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Morat\u00f3, X., Pytel, V., Jofresa, S., Ruiz, A., and Boada, M. (2022). Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer\u2019s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169305"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s13311-022-01201-2","article-title":"Disease-Modifying Therapies for Alzheimer\u2019s Disease: More Questions than Answers","volume":"19","author":"Golde","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamaneurol.2020.4478","article-title":"Possible Consequences of the Approval of a Disease-Modifying Therapy for Alzheimer Disease","volume":"78","author":"Musiek","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1474-4422(23)00274-0","article-title":"Preparing for disease-modifying therapies in Alzheimer\u2019s disease","volume":"22","author":"Belder","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","article-title":"Biomarkers for Alzheimer\u2019s disease\u2014Preparing for a new era of disease-modifying therapies","volume":"26","author":"Zetterberg","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/13543784.2020.1795127","article-title":"Discontinued disease-modifying therapies for Alzheimer\u2019s disease: Status and future perspectives","volume":"29","author":"Imbimbo","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_66","first-page":"e934077-1","article-title":"Editorial: Targets for Disease-Modifying Therapies in Alzheimer\u2019s Disease, Including Amyloid \u03b2 and Tau Protein","volume":"27","author":"Parums","year":"2021","journal-title":"Med. Sci. Monit."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.neurol.2022.02.456","article-title":"Therapeutic news in Alzheimer\u2019s disease: Soon a disease-modifying therapy?","volume":"178","author":"Villain","year":"2022","journal-title":"Rev. Neurol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e12295","DOI":"10.1002\/trc2.12295","article-title":"Alzheimer\u2019s disease drug development pipeline: 2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e200127","DOI":"10.1212\/CPJ.0000000000200127","article-title":"Meaningful Clinical Changes in Alzheimer Disease Measured with the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings","volume":"13","author":"Wessels","year":"2023","journal-title":"Neurol. Clin. Pract."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e12050","DOI":"10.1002\/trc2.12050","article-title":"Alzheimer\u2019s disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e12385","DOI":"10.1002\/trc2.12385","article-title":"Alzheimer\u2019s disease drug development pipeline: 2023","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13195-020-00662-x","article-title":"Repurposed agents in the Alzheimer\u2019s disease drug development pipeline","volume":"12","author":"Bauzon","year":"2020","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Haass, C., and Selkoe, D. (2022). If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?. PLoS Biol., 20.","DOI":"10.1371\/journal.pbio.3001694"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: New insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Behl, T., Kaur, I., Fratila, O., Brata, R., and Bungau, S. (2020). Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-\u03b2 Cascade in Alzheimer\u2019s Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207443"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Mallah, K., Couch, C., Borucki, D.M., Toutonji, A., Alshareef, M., and Tomlinson, S. (2020). Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go from Here?. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.02021"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Lee, K.H., Cha, M., and Lee, B.H. (2020). Neuroprotective Effect of Antioxidants in the Brain. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197152"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2022.02.034","article-title":"Versatile nanomaterials for Alzheimer\u2019s disease: Pathogenesis inspired disease-modifying therapy","volume":"345","author":"Xi","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"111452","DOI":"10.1016\/j.mad.2021.111452","article-title":"Molecular mechanisms of altered adult hippocampal neurogenesis in Alzheimer\u2019s disease","volume":"195","author":"Liu","year":"2021","journal-title":"Mech. Ageing Dev."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Doroszkiewicz, J., and Mroczko, B. (2022). New Possibilities in the Therapeutic Approach to Alzheimer\u2019s Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23168902"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Colavitta, M.F., and Barrantes, F.J. (2023). Therapeutic Strategies Aimed at Improving Neuroplasticity in Alzheimer Disease. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15082052"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ijbiomac.2020.11.192","article-title":"Review on Alzheimer\u2019s disease: Inhibition of amyloid beta and tau tangle formation","volume":"167","author":"Ashrafian","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e933084-1","DOI":"10.12659\/MSM.933084","article-title":"The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer\u2019s Disease","volume":"27","author":"Yin","year":"2021","journal-title":"Med. Sci. Monit."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.7150\/ijbs.57078","article-title":"Interaction between A\u03b2 and Tau in the Pathogenesis of Alzheimer\u2019s Disease","volume":"17","author":"Zhang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-Related Imaging Abnormalities and \u03b2-Amyloid\u2013Targeting Antibodies","volume":"79","author":"Filippi","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","article-title":"Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: Challenges, successes and future","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"101496","DOI":"10.1016\/j.arr.2021.101496","article-title":"Past, present and future of therapeutic strategies against amyloid-\u03b2 peptides in Alzheimer\u2019s disease: A systematic review","volume":"72","author":"Jeremic","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Shi, M., Chu, F., Zhu, F., and Zhu, J. (2022). Impact of Anti-amyloid-\u03b2 Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer\u2019s Disease: A Focus on Aducanumab and Lecanemab. Front. Aging Neurosci., 14.","DOI":"10.3389\/fnagi.2022.870517"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2023.11703","article-title":"Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease","volume":"330","author":"Rabinovici","year":"2023","journal-title":"JAMA"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Fedele, E. (2023). Anti-Amyloid Therapies for Alzheimer\u2019s Disease and the Amyloid Cascade Hypothesis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914499"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40263-024-01067-2","article-title":"Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer\u2019s Disease: A Systematic Review and Network Meta-Analysis","volume":"38","author":"Qiao","year":"2024","journal-title":"CNS Drugs"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s43587-024-00597-0","article-title":"Targeting aging and age-related diseases with vaccines","volume":"4","author":"Wu","year":"2024","journal-title":"Nat. Aging"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: Current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"11","DOI":"10.20517\/and.2022.16","article-title":"Tau-targeting therapy in Alzheimer\u2019s disease: Critical advances and future opportunities","volume":"2","author":"Guo","year":"2022","journal-title":"Ageing Neurodegener. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"108104","DOI":"10.1016\/j.neuropharm.2020.108104","article-title":"Tau immunotherapies: Lessons learned, current status and future considerations","volume":"175","author":"Sigurdsson","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12974-023-02853-3","article-title":"Tau and neuroinflammation in Alzheimer\u2019s disease: Interplay mechanisms and clinical translation","volume":"20","author":"Chen","year":"2023","journal-title":"J. Neuroinflamm."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neuint.2018.02.006","article-title":"The small heat shock proteins, especially HspB4 and HspB5 are promising protectants in neurodegenerative diseases","volume":"115","author":"Zhu","year":"2018","journal-title":"Neurochem. Int."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Campanella, C., Pace, A., Bavisotto, C.C., Marzullo, P., Gammazza, A.M., Buscemi, S., and Piccionello, A.P. (2018). Heat Shock Proteins in Alzheimer\u2019s Disease: Role and Targeting. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092603"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1901844","DOI":"10.1002\/advs.201901844","article-title":"Heat Shock Protein Inspired Nanochaperones Restore Amyloid-\u03b2 Homeostasis for Preventative Therapy of Alzheimer\u2019s Disease","volume":"6","author":"Yang","year":"2019","journal-title":"Adv. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"117957352090739","DOI":"10.1177\/1179573520907397","article-title":"Current and Future Treatments in Alzheimer Disease: An Update","volume":"12","author":"Yiannopoulou","year":"2020","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Pardo-Moreno, T., Gonz\u00e1lez-Acedo, A., Rivas-Dom\u00ednguez, A., Garc\u00eda-Morales, V., Garc\u00eda-Cozar, F.J., Ramos-Rodr\u00edguez, J.J., and Melguizo-Rodr\u00edguez, L. (2022). Therapeutic Approach to Alzheimer\u2019s Disease: Current Treatments and New Perspectives. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061117"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1126\/science.abi6401","article-title":"Treatments for Alzheimer\u2019s disease emerge","volume":"373","author":"Selkoe","year":"2021","journal-title":"Science"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"173554","DOI":"10.1016\/j.ejphar.2020.173554","article-title":"Alzheimer\u2019s disease: Recent treatment strategies","volume":"887","author":"Vaz","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_106","first-page":"1","article-title":"New approaches to symptomatic treatments for Alzheimer\u2019s disease","volume":"16","author":"Cummings","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2200398","DOI":"10.1002\/ardp.202200398","article-title":"Development of new Alzheimer\u2019s disease drug candidates using donepezil as a key model","volume":"356","author":"Eissa","year":"2022","journal-title":"Arch. Der Pharm."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/14737175.2024.2355981","article-title":"The donepezil transdermal system for the treatment of patients with mild, moderate, or severe Alzheimer\u2019s disease: A critical review","volume":"24","author":"Buck","year":"2024","journal-title":"Expert Rev. Neurother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00580-023-03487-w","article-title":"Donepezil-based combination therapy for Alzheimer\u2019s disease and related neuropathies","volume":"32","author":"Ekundayo","year":"2023","journal-title":"Comp. Clin. Pathol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"100100","DOI":"10.1016\/j.crphar.2022.100100","article-title":"Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer\u2019s disease in Wistar rats","volume":"3","author":"Manickam","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_111","first-page":"128","article-title":"Therapeutic and medicinal effects of snowdrop (Galanthus spp.) in Alzheimer\u2019s disease: A review","volume":"12","author":"Kaboudi","year":"2023","journal-title":"J. Educ. Health Promot."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"167","DOI":"10.22270\/jddt.v12i4.5426","article-title":"Galantamine: A Review Update","volume":"12","author":"Kaur","year":"2022","journal-title":"J. Drug Deliv. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11240-020-01911-5","article-title":"Use of galantamine in the treatment of Alzheimer\u2019s disease and strategies to optimize its biosynthesis using the in vitro culture technique","volume":"143","author":"Santos","year":"2020","journal-title":"Plant Cell Tissue Organ Cult. (PCTOC)"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/nmt-2020-0052","article-title":"Evaluation of rivastigmine in Alzheimer\u2019s disease","volume":"11","author":"Nguyen","year":"2021","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1872208316666220302115901","article-title":"Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer\u2019s Disease","volume":"16","author":"Saeedi","year":"2022","journal-title":"Recent Pat. Biotechnol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41398-020-0709-x","article-title":"Rivastigmine modifies the \u03b1-secretase pathway and potentially early Alzheimer\u2019s disease","volume":"10","author":"Ray","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Vicente-Zurdo, D., Rosales-Conrado, N., Le\u00f3n-Gonz\u00e1lez, M.E., Brunetti, L., Piemontese, L., Pereira-Santos, A.R., Cardoso, S.M., Madrid, Y., Chaves, S., and Santos, M.A. (2022). Novel Rivastigmine Derivatives as Promising Multi-Target Compounds for Potential Treatment of Alzheimer\u2019s Disease. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071510"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ijbiomac.2020.01.134","article-title":"Probing the interaction of Rivastigmine Tartrate, an important Alzheimer\u2019s drug, with serum albumin: Attempting treatment of Alzheimer\u2019s disease","volume":"148","author":"Shamsi","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00210-021-02096-0","article-title":"Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer\u2019s disease","volume":"394","author":"Rompicherla","year":"2021","journal-title":"Naunyn-Schmiedeberg S Arch. Pharmacol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"123809","DOI":"10.1016\/j.ijpharm.2024.123809","article-title":"Rivastigmine nasal spray for the treatment of Alzheimer\u2019s Disease: Olfactory deposition and brain delivery","volume":"652","author":"Guo","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Ezzat, S.M., Salem, M.A., Mahdy, N.M.E., and Ragab, M.F. (2021). Rivastigmine. Naturally Occurring Chemicals Against Alzheimer\u2019s Disease, Elsevier.","DOI":"10.1016\/B978-0-12-819212-2.00007-4"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/ibra.12098","article-title":"Basic information about memantine and its treatment of Alzheimer\u2019s disease and other clinical applications","volume":"9","author":"Tang","year":"2023","journal-title":"Ibrain"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"113409","DOI":"10.1016\/j.psychres.2020.113409","article-title":"Galantamine-Memantine combination in the treatment of Alzheimer\u2019s disease and beyond","volume":"293","author":"Koola","year":"2020","journal-title":"Psychiatry Res."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Marotta, G., Basagni, F., Rosini, M., and Minarini, A. (2020). Memantine Derivatives as Multitarget Agents in Alzheimer\u2019s Disease. Molecules, 25.","DOI":"10.3390\/molecules25174005"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"114354","DOI":"10.1016\/j.ejmech.2022.114354","article-title":"Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer\u2019s disease","volume":"236","author":"Turcu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e13371","DOI":"10.1111\/acel.13371","article-title":"Therapeutic efficacy of novel memantine nitrate MN-08 in animal models of Alzheimer\u2019s disease","volume":"20","author":"Wu","year":"2021","journal-title":"Aging Cell"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s43856-024-00527-6","article-title":"Combined use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer\u2019s disease patients","volume":"4","author":"Yaghmaei","year":"2024","journal-title":"Commun. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/03007995.2023.2182530","article-title":"Extemporaneous combination of donepezil and memantine to treat dementia in Alzheimer disease: Evidence from Italian real-world data","volume":"39","author":"Padovani","year":"2023","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s43045-024-00405-w","article-title":"Are there links between Alzheimer\u2019s disease and ADHD? The efficacy of acetylcholinesterase inhibitors and NMDA receptor antagonists in controlling ADHD symptoms: A systematic review","volume":"31","author":"Dezfouli","year":"2024","journal-title":"Middle East Curr. Psychiatry"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/psyg.12944","article-title":"Aducanumab for the treatment of Alzheimer\u2019s disease: A systematic review","volume":"23","author":"Rahman","year":"2023","journal-title":"Psychogeriatrics"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Wojtunik-Kulesza, K., Rudkowska, M., and Orze\u0142-Sajd\u0142owska, A. (2023). Aducanumab\u2014Hope or Disappointment for Alzheimer\u2019s Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054367"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2147\/CIA.S325026","article-title":"Role of Aducanumab in the Treatment of Alzheimer\u2019s Disease: Challenges and Opportunities","volume":"17","author":"Vaz","year":"2022","journal-title":"Clin. Interv. Aging"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1474-4422(19)30480-6","article-title":"A resurrection of aducanumab for Alzheimer\u2019s disease","volume":"19","author":"Schneider","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","article-title":"Approval of Aducanumab for Alzheimer Disease\u2014The FDA\u2019s Perspective","volume":"181","author":"Dunn","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/d41573-023-00004-0","article-title":"FDA approves second anti-amyloid antibody for Alzheimer disease","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/d41586-023-00030-3","article-title":"FDA approves Alzheimer\u2019s drug lecanemab amid safety concerns","volume":"613","author":"Reardon","year":"2023","journal-title":"Nature"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"03946320231209839","DOI":"10.1177\/03946320231209839","article-title":"Novel anti-amyloid-beta (A\u03b2) monoclonal antibody lecanemab for Alzheimer\u2019s disease: A systematic review","volume":"37","author":"Chowdhury","year":"2023","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1254\/fpj.24005","article-title":"Mechanism of action and clinical trial results of Lecanemab (Leqembi\u00ae 200 mg, 500 mg for Intravenous Infusion), a novel treatment for Alzheimer\u2019s disease","volume":"159","author":"Niidome","year":"2024","journal-title":"Folia Pharmacol. Jpn."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"Swanson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"149018","DOI":"10.1016\/j.brainres.2024.149018","article-title":"Immunotherapeutic approaches for Alzheimer\u2019s disease: Exploring active and passive vaccine progress","volume":"1840","author":"Bhadane","year":"2024","journal-title":"Brain Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e24289","DOI":"10.1002\/pep2.24289","article-title":"Current peptide vaccine and immunotherapy approaches against Alzheimer\u2019s disease","volume":"115","author":"Parrocha","year":"2022","journal-title":"Pept. Sci."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/WAD.0000000000000592","article-title":"Alzheimer Disease: A New Beginning in Therapeutics","volume":"37","author":"Honig","year":"2023","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"255","DOI":"10.37349\/en.2024.00048","article-title":"Current therapeutics for Alzheimer\u2019s disease and clinical trials","volume":"3","author":"Xiao","year":"2024","journal-title":"Explor. Neurosci."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1002\/alz.13031","article-title":"Targeting amyloid \u03b2 in Alzheimer\u2019s disease: Meta-analysis of low-dose solanezumab in Alzheimer\u2019s disease with mild dementia studies","volume":"19","author":"Holdridge","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of Solanezumab in Preclinical Alzheimer\u2019s Disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/1386207326666230419095813","article-title":"Safety Analysis of Bapineuzumab in the Treatment of Mild to Moderate Alzheimer\u2019s Disease: A Systematic Review and Meta-Analysis","volume":"27","author":"Gao","year":"2024","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"102012","DOI":"10.1016\/j.arr.2023.102012","article-title":"Efficacy and safety of anti-amyloid-\u03b2 monoclonal antibodies in current Alzheimer\u2019s disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis","volume":"90","author":"Jeremic","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Hao, Y., Dong, M., Sun, Y., Duan, X., and Niu, W. (2023). Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-\u00e0-vis placebo in mild or moderate Alzheimer\u2019s disease. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1147757"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Nea\u021bu, M., Covaliu, A., Ioni\u021b\u0103, I., Jugurt, A., Davidescu, E.I., and Popescu, B.O. (2023). Monoclonal Antibody Therapy in Alzheimer\u2019s Disease. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16010060"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two Phase 3 Trials of Gantenerumab in Early Alzheimer\u2019s Disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, Aducanumab, and Gantenerumab\u2014Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer\u2019s Disease","volume":"20","author":"Johannesson","year":"2023","journal-title":"Neurotherapeutics"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/14737175.2024.2367016","article-title":"Gantenerumab for early Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"24","author":"Leite","year":"2024","journal-title":"Expert Rev. Neurother."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/alz.13532","article-title":"Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE \u03b54 homozygotes","volume":"20","author":"Riviere","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_154","first-page":"e40138","article-title":"Attempts to Develop Vaccines Against Alzheimer\u2019s Disease: A Systematic Review of Ongoing and Completed Vaccination Trials in Humans","volume":"15","author":"Thakur","year":"2023","journal-title":"Cureus"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4155\/ppa-2022-0031","article-title":"Ever-expanding landscape: Alzheimer\u2019s\u2014New targets and new patents","volume":"11","author":"Egunlusi","year":"2022","journal-title":"Pharm. Pat. Anal."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-201027","article-title":"Selective Secretase Targeting for Alzheimer\u2019s Disease Therapy","volume":"81","author":"Miranda","year":"2021","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/JAD-180145","article-title":"Alzheimer\u2019s Disease: Advances in Drug Development","volume":"65","author":"Piton","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"340","DOI":"10.61186\/rbmb.12.2.340","article-title":"\u03b3-Secretase Inhibitors Selected by Molecular Docking, to Develop a New Drug Against Alzheimer\u2019s Disease","volume":"12","author":"Medina","year":"2023","journal-title":"Rep. Biochem. Mol. Biol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/fcp.12861","article-title":"Molecular mechanisms of Alzheimer\u2019s disease: From therapeutic targets to promising drugs","volume":"37","author":"Alan","year":"2023","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.2174\/1381612826666200211121416","article-title":"A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer\u2019s Disease","volume":"26","author":"Ettcheto","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e12123","DOI":"10.1002\/trc2.12123","article-title":"Lanabecestat: Neuroimaging results in early symptomatic Alzheimer\u2019s disease","volume":"7","author":"Zimmer","year":"2021","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1016\/S0140-6736(18)31425-9","article-title":"Alzheimer\u2019s disease research: The future of BACE inhibitors","volume":"391","author":"Burki","year":"2018","journal-title":"Lancet"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer\u2019s Disease","volume":"378","author":"Egan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized Trial of Verubecestat for Prodromal Alzheimer\u2019s Disease","volume":"380","author":"Egan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13195-018-0415-6","article-title":"Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer\u2019s disease: Randomized, double-blind, placebo-controlled study","volume":"10","author":"Timmers","year":"2018","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"15262","DOI":"10.1021\/acs.jmedchem.1c01300","article-title":"Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious \u03b2-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer\u2019s Disease","volume":"64","author":"Machauer","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e9316","DOI":"10.15252\/emmm.201809316","article-title":"The BACE -1 inhibitor CNP 520 for prevention trials in Alzheimer\u2019s disease","volume":"10","author":"Neumann","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3233\/JAD-181001","article-title":"Methylene Blue Inhibits Formation of Tau Fibrils but not of Granular Tau Oligomers: A Plausible Key to Understanding Failure of a Clinical Trial for Alzheimer\u2019s Disease","volume":"68","author":"Soeda","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Berrocal, M., Caballero-Bermejo, M., Gutierrez-Merino, C., and Mata, A.M. (2019). Methylene Blue Blocks and Reverses the Inhibitory Effect of Tau on PMCA Function. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20143521"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ijbiomac.2018.08.038","article-title":"Exploring the effects of methylene blue on amyloid fibrillogenesis of lysozyme","volume":"119","author":"How","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/1061186X.2018.1474361","article-title":"Drug development for Alzheimer\u2019s disease: Review","volume":"27","author":"Lao","year":"2018","journal-title":"J. Drug Target."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"688","DOI":"10.34172\/apb.2023.071","article-title":"Role of GSK-3\u03b2 Inhibitors: New Promises and Opportunities for Alzheimer\u2019s Disease","volume":"13","author":"Shri","year":"2023","journal-title":"Adv. Pharm. Bull."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Dong, Y., Lu, J., Zhang, S., Chen, L., Wen, J., Wang, F., Mao, Y., Li, L., Zhang, J., and Liao, S. (2023). Design, synthesis and bioevaluation of 1,2,4-thiadiazolidine-3,5-dione derivatives as potential GSK-3\u03b2 inhibitors for the treatment of Alzheimer\u2019s disease. Bioorganic Chem., 134.","DOI":"10.1016\/j.bioorg.2023.106446"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e12044","DOI":"10.1002\/trc2.12044","article-title":"Targeting dementias through cancer kinases inhibition","volume":"6","author":"Fagiani","year":"2020","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Ramos, R., and Vale, N. (2024). Dual Drug Repurposing: The Example of Saracatinib. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25084565"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Tridente, G., Jana, A., Nath, A., and Ashraf, G.M. (2023). Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders. Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders, Academic Press.","DOI":"10.1016\/B978-0-443-18677-6.00015-4"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ijnp\/pyaa048","article-title":"The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer\u2019s Disease: A Preclinical Study in APP\/PS1 Transgenic Mice","volume":"23","author":"Wang","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"135281","DOI":"10.1016\/j.neulet.2020.135281","article-title":"Roflumilast: A potential drug for the treatment of cognitive impairment?","volume":"736","author":"Sugin","year":"2020","journal-title":"Neurosci. Lett."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ejmech.2018.12.013","article-title":"Synthesis and evaluation of clioquinol-rolipram\/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer\u2019s disease","volume":"163","author":"Hu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12640-022-00482-x","article-title":"Roflumilast Reduces Pathological Symptoms of Sporadic Alzheimer\u2019s Disease in Rats Produced by Intracerebroventricular Streptozotocin by Inhibiting NF-\u03baB\/BACE-1 Mediated A\u03b2 Production in the Hippocampus and Activating the cAMP\/BDNF Signalling Pathway","volume":"40","author":"Hasan","year":"2022","journal-title":"Neurotox. Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e209131","DOI":"10.1212\/WNL.0000000000209131","article-title":"Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease","volume":"102","author":"Adesuyan","year":"2024","journal-title":"Neurology"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"e12179","DOI":"10.1002\/trc2.12179","article-title":"Alzheimer\u2019s disease drug development pipeline: 2021","volume":"7","author":"Cummings","year":"2021","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e12465","DOI":"10.1002\/trc2.12465","article-title":"Alzheimer\u2019s disease drug development pipeline: 2024","volume":"10","author":"Cummings","year":"2024","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Huang, L.-K., Kuan, Y.-C., Lin, H.-W., and Hu, C.-J. (2023). Clinical trials of new drugs for Alzheimer disease: A 2020\u20132023 update. J. Biomed. Sci., 30.","DOI":"10.1186\/s12929-023-00976-6"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/alz.12213","article-title":"Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019","volume":"17","author":"Knopman","year":"2020","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s40265-021-01569-z","article-title":"Aducanumab: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3233\/JAD-215065","article-title":"A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer\u2019s Disease","volume":"83","author":"Mukhopadhyay","year":"2021","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_189","unstructured":"(2024, August 17). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/search?cond=Alzheimer%27s%20Disease."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13311-022-01185-z","article-title":"Heterogeneity in Alzheimer\u2019s Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials","volume":"19","author":"Duara","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1515\/revneuro-2023-0033","article-title":"A review of neuroimaging-based data-driven approach for Alzheimer\u2019s disease heterogeneity analysis","volume":"35","author":"Liu","year":"2024","journal-title":"Rev. Neurosci."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Wei, H., Wu, C., Yuan, Y., and Lai, L. (2023). Uncovering the Achilles heel of genetic heterogeneity: Machine learning-based classification and immunological properties of necroptosis clusters in Alzheimer\u2019s disease. Front. Aging Neurosci., 15.","DOI":"10.3389\/fnagi.2023.1249682"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/cpt.1782","article-title":"Challenges in Alzheimer\u2019s Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data","volume":"107","author":"Conrado","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Abduljawad, A.A., Elawad, M.A., Elkhalifa, M.E.M., Ahmed, A., Hamdoon, A.A.E., Salim, L.H.M., Ashraf, M., Ayaz, M., Hassan, S.S.U., and Bungau, S. (2022). Alzheimer\u2019s Disease as a Major Public Health Concern: Role of Dietary Saponins in Mitigating Neurodegenerative Disorders and Their Underlying Mechanisms. Molecules, 27.","DOI":"10.3390\/molecules27206804"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Ribba, B. (2023). Reinforcement learning as an innovative model-based approach: Examples from precision dosing, digital health and computational psychiatry. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1094281"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/QAI.0000000000000037","article-title":"Regulatory Challenges Associated with Conducting Multicountry Clinical Trials in Resource-Limited Settings","volume":"65","author":"Ndebele","year":"2014","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12939-018-0748-6","article-title":"Barriers for conducting clinical trials in developing countries\u2014A systematic review","volume":"17","author":"Alemayehu","year":"2018","journal-title":"Int. J. Equity Health"},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Sinsky, J., Pichlerova, K., and Hanes, J. (2021). Tau Protein Interaction Partners and Their Roles in Alzheimer\u2019s Disease and Other Tauopathies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179207"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Alquezar, C., Arya, S., and Kao, A.W. (2021). Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation. Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.595532"},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Yang, J., Zhi, W., and Wang, L. (2024). Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review. Molecules, 29.","DOI":"10.3390\/molecules29122812"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"S555","DOI":"10.3233\/JAD-179937","article-title":"Tau Immunotherapies for Alzheimer\u2019s Disease and Related Tauopathies: Progress and Potential Pitfalls1","volume":"64","author":"Sigurdsson","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12974-020-01878-2","article-title":"TREM2 ectodomain and its soluble form in Alzheimer\u2019s disease","volume":"17","author":"Yang","year":"2020","journal-title":"J. Neuroinflamm."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Huang, W., Huang, J., Huang, N., and Luo, Y. (2023). The role of TREM2 in Alzheimer\u2019s disease: From the perspective of Tau. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1280257"},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Shi, Q., Gutierrez, R.A., and Bhat, M.A. (2024). Microglia, Trem2, and Neurodegeneration. Neuroscientist, 10738584241254118.","DOI":"10.1177\/10738584241254118"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"110020","DOI":"10.1016\/j.neuropharm.2024.110020","article-title":"Microglia and TREM2","volume":"257","author":"Pocock","year":"2024","journal-title":"Neuropharmacology"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"100149","DOI":"10.1016\/j.crphar.2022.100149","article-title":"Role of pro-inflammatory cytokines in Alzheimer\u2019s disease and neuroprotective effects of pegylated self-assembled nanoscaffolds","volume":"4","author":"Rani","year":"2023","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Simpson, D.S.A., and Oliver, P.L. (2020). ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease. Antioxidants, 9.","DOI":"10.3390\/antiox9080743"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s12264-016-0055-4","article-title":"Inflammatory Cytokines and Alzheimer\u2019s Disease: A Review from the Perspective of Genetic Polymorphisms","volume":"32","author":"Su","year":"2016","journal-title":"Neurosci. Bull."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.semcdb.2022.03.032","article-title":"Novel approaches to increase synaptic resilience as potential treatments for Alzheimer\u2019s disease","volume":"139","author":"Pham","year":"2023","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2174\/1871527316666170113120853","article-title":"Synaptic Plasticity, Dementia and Alzheimer Disease","volume":"16","author":"Skaper","year":"2017","journal-title":"CNS Neurol. Disord.\u2014Drug Targets"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jconrel.2023.01.074","article-title":"Brain-neuron targeted nanoparticles for peptide synergy therapy at dual-target of Alzheimer\u2019s disease","volume":"355","author":"Guo","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.immuni.2023.05.010","article-title":"Neuroprotective protein ADNP-dependent histone remodeling complex promotes T helper 2 immune cell differentiation","volume":"56","author":"Ferreira","year":"2023","journal-title":"Immunity"},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"AlMansoori, M.E., Jemimah, S., Abuhantash, F., and AlShehhi, A. (2024). Predicting early Alzheimer\u2019s with blood biomarkers and clinical features. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-56489-1"},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Kesu, S.M.R., Sinha, N., and Ramasangu, H. (2024). Cellular Automata Framework for Dementia Classification Using Explainable AI. Eng. Proc., 68.","DOI":"10.3390\/engproc2024068036"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Arafah, A., Khatoon, S., Rasool, I., Khan, A., Rather, M.A., Abujabal, K.A., Faqih, Y.A.H., Rashid, H., Rashid, S.M., and Ahmad, S.B. (2023). The Future of Precision Medicine in the Cure of Alzheimer\u2019s Disease. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020335"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"e000079","DOI":"10.1136\/bmjno-2020-000079","article-title":"Alzheimer\u2019s disease: From basic science to precision medicine approach","volume":"2","author":"Forloni","year":"2020","journal-title":"BMJ Neurol. Open"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3233\/JAD-180766","article-title":"Treatment Combinations for Alzheimer\u2019s Disease: Current and Future Pharmacotherapy Options","volume":"67","author":"Cummings","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_218","first-page":"1751","article-title":"Anticancer Prodrugs\u2014Three Decades of Design","volume":"4","author":"Horani","year":"2015","journal-title":"World J. Pharm. Pharm. Sci."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"140","DOI":"10.37586\/2686-8636-2-2024-140-144","article-title":"Combination Drug Therapy for the Management of Alzheimer\u2019s Disease","volume":"21","author":"Dudchenko","year":"2024","journal-title":"Russ. J. Geriatr. Med."},{"key":"ref_220","first-page":"631","article-title":"Personalizing the Care and Treatment of Alzheimer\u2019s Disease: An Overview","volume":"14","author":"Strac","year":"2021","journal-title":"Pharmacogenom. Pers. Med."},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate-Armand, C., Yen, F.T., and Arab-Tehrany, E. (2022). Alzheimer\u2019s Disease: Treatment Strategies and Their Limitations. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213954"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/29\/21\/5131\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:24:31Z","timestamp":1760113471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/29\/21\/5131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":221,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["molecules29215131"],"URL":"https:\/\/doi.org\/10.3390\/molecules29215131","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]}}}